Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut‐Offs to Use?
Open Access
- 1 January 2021
- journal article
- review article
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2021 (1)
Abstract
Chronic liver diseases (CLDs) are a public health problem, even if frequently they are underdiagnosed. Hepatic steatosis (HS), encountered not only in nonalcoholic fatty liver disease (NAFLD) but also in chronic viral hepatitis, alcoholic liver disease, etc., plays an important role in fibrosis progression, regardless of CLD etiology; thus, detection and quantification of HS are imperative. Controlled attenuation parameter (CAP) feature, implemented in the FibroScan® device, measures the attenuation of the US beam as it passes through the liver. It is a noninvasive technique, feasible and well accepted by patients, with lower costs than other diagnostic techniques, with acceptable accuracy for HS quantification. Multiple studies have been published regarding CAP performance to quantify steatosis, but due to the heterogeneity of CLD etiologies, of steatosis prevalence, etc., it had widely variable calculated cut‐off values, which in turn limited the day‐to‐day utility of CAP measurements in clinical practice. This paper reviews published studies trying to suggest cut‐off values usable in clinical practice.Keywords
Funding Information
- “Victor Babeş” University of Medicine (2EXP/2020)
- Pharmacy Timişoara-Acronim: BRLIV (2EXP/2020)
This publication has 53 references indexed in Scilit:
- Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragmentsAlimentary Pharmacology & Therapeutics, 2013
- Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastographyEuropean Journal of Gastroenterology & Hepatology, 2013
- Indications de la ponction biopsie hépatique au cours des maladies parenchymateuses diffuses du foieLa Presse Médicale, 2012
- Non‐invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastographyLiver International, 2012
- Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastographyLiver International, 2012
- Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis CJournal of Viral Hepatitis, 2011
- Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various CausesUltrasound in Medicine & Biology, 2010
- Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver DiseaseHepatology, 2010
- Liver biopsy: The best, not the gold standardJournal of Hepatology, 2009
- Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis TrialClinical Gastroenterology and Hepatology, 2007